Compare GSK plc (GSK) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? GSK plc trades at $48.29 (market cap $92.78B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $37.8 (market cap $63.57B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| GSK | RELX | |
|---|---|---|
Market Cap | $92.78B | $63.57B |
Volume | 5,756,402 | 1,602,093 |
Sector | Health | Industrials |
52-Week High | $61.18 | $46.80 |
52-Week Low | $43.24 | $27.73 |
Typical Hold Time | 93 Days | — |
Enterprise Value | $112.77B | $75.05B |
Dividend Yield | 3.92% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by three consecutive quarterly earnings beats. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology growth targeting £40B in sales. Cash flow trends show consistent operational strength with $7.7B from operations in 2025.
GSK presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 14.84 P/E ratio and dividend yield, but faces headwinds from HIV patent expirations and bearish technical indicators. Analyst consensus leans cautious with 55% hold ratings, suggesting patience may be warranted despite the company's solid operational performance.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →
